Key result
Lean nonalcoholic fatty liver disease is commonly associated with sarcopenia, and their coexistence exacerbates metabolic disorders such as insulin resistance and systemic inflammation.
Why the study?
Lean NAFLD commonly co-occurs with sarcopenia through shared pathological features such as visceral obesity, insulin resistance, and metabolic inflammation.
This review highlights the bidirectional pathological relationship between lean NAFLD and sarcopenia, emphasizing the need for targeted strategies to manage these interconnected conditions.
Answers are grounded in this paper and cite their sources.
Lean NAFLD may warrant sarcopenia screening; leaves open causality and interventional targets.
Nonalcoholic fatty liver disease (NAFLD) has become one of the most common chronic liver diseases in the world. The risk factor for NAFLD is often considered to be obesity, but it can also occur in people with lean type, which is defined as lean NAFLD. Lean NAFLD is commonly associated with sarcopenia, a progressive loss of muscle quantity and quality. The pathological features of lean NAFLD such as visceral obesity, insulin resistance, and metabolic inflammation are inducers of sarcopenia, whereas loss of muscle mass and function further exacerbates ectopic fat accumulation and lean NAFLD. Therefore, we discussed the association of sarcopenia and lean NAFLD, summarized the underlying pathological mechanisms, and proposed potential strategies to reduce the risks of lean NAFLD and sarcopenia in this review.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2023) conducted a review in Lean nonalcoholic fatty liver disease and sarcopenia. Lean nonalcoholic fatty liver disease is commonly associated with sarcopenia, and their coexistence exacerbates metabolic disorders such as insulin resistance and systemic inflammation.
Synapse has enriched 10 related papers. Consider them for comparative context: